Björn Frendéus
Chief Scientific Officer BioInvent
Seminars
Thursday 25th March 2027
Targeting TNFR2 for Cancer Immunotherapy & Beyond
10:00 am
- Antibodies to TNFR2 employ different modes of actions to trigger antitumor immunity
- Ligand-blocking a TNFR2 turns cold tumors hot by a differentiated mechanism involving Treg depletion, myeloid reprogramming, and induction of CD8+ T-cells, stimulating tertiary lymphoid structure formation
- Agonist antibodies expand and activate CD4+ and CD8+ T-cells and NK-cells, activating a broad IFN response, indicating potential in vaccine and cell therapy, and the implications for design of TNFR2 agonist antibodies for I&I